Numerous updates have been added to these guidelines. In the diagnostics field, the advent of an international standard for CMV viral load testing and reporting of values in IU/mL will eventually allow for harmonization of viral load tests with subsequent development of thresholds for preemptive and diagnostic protocols. QNAT is increasingly used and preferred for diagnosis, decisions regarding preemptive therapy, and monitoring response to therapy. There is substantially more evidence to support the use of immunodiagnostics as an adjunct tool to predict the risk of CMV disease. Vaccine development continues and holds increasing promise as a future prevention strategy. Updates in the prevention field include the effectiveness of prolonging prophylaxis in D+/R- kidney recipients from 100 to 200 days and from 3 to 12 months in lung transplant recipients. Trials with carefully executed preemptive therapy, using low viral load thresholds, demonstrate similar outcomes to universal prophylaxis including similar long-term graft survival. Some experts are using a hybrid approach (prophylaxis followed by preemptive therapy) with increased frequency. Valganciclovir is increasingly used as the preferred agent for treatment (except for life-threatening cases and situations with questionable drug bioavailability or noncompliance). Additional specific recommendations on the use of IVIG with CMV treatment are included. Differences between different algorithms for determining estimated glomerular filtration rate and the risk of overdosing have been highlighted. Diagnostic resistance mutations have been updated and the clinical management algorithm for ganciclovir-resistant CMV has been slightly modified to clarify decision-making criteria. Alternative therapy has been updated to reflect current experimental drugs. In the pediatrics section, valganciclovir is included in the prevention and treatment of CMV due to new data detailing the pharmacokinetics of valganciclovir in pediatrics. Prophylaxis, preemptive therapy, and hybrid regimens are all now recommended regimens for CMV prevention in children, as emerging data support each of these strategies, albeit without comparative efficacy studies.
The authors thank Frank Lindo Verissimo, Danielle Viau, and Catherin Parker of The Transplantation Society for their administrative support and Dr. Michael Boeckh for detailed review. These guidelines are dedicated in memory of Dr. Mark D. Pescovitz (1955–2010), a participant in the last set of guidelines and major contributor to the field of organ transplantation and specifically CMV. The authors miss him dearly.
Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus
in solid organ transplantation. Transplantation 2010; 89: 779.
Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008; 336: 1049.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924.
Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008; 337: a744.
Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ 2008; 336: 1170.
Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106.
Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851.
Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
Weber B, Fall EM, Berger A, et al. Screening of blood donors for human cytomegalovirus
(HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol 1999; 14: 173.
Seed CR, Piscitelli LM, Maine GT, et al. Validation of an automated immunoglobulin G-only cytomegalovirus
) antibody screening assay and an assessment of the risk of transfusion transmitted CMV
from seronegative blood. Transfusion 2009; 49: 134.
Lazzarotto T, Brojanac S, Maine GT, et al. Search for cytomegalovirus
-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays. Clin Diagn Lab Immunol 1997; 4: 483.
Weber B, Berger A, Rabenau H. Human cytomegalovirus
infection: diagnostic potential of recombinant antigens for cytomegalovirus
antibody detection. J Virol Methods 2001; 96: 157.
Preiksaitis JK, Sandhu J, Strautman M. The risk of transfusion-acquired CMV
infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV
antibody (1984 to 1996): experience at a single Canadian center. Transfusion 2002; 42: 396.
Ritter M, Schmidt T, Dirks J, et al. Cytomegalovirus
-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol 2013; 43: 1099.
Schmidt T, Ritter M, Dirks J, et al. Cytomegalovirus
-specific T-cell immunity to assign the infection status in individuals with passive immunity: a proof of principle. J Clin Virol 2012; 54: 272.
Pillay D, Ali AA, Liu SF, et al. The prognostic significance of positive CMV
cultures during surveillance of renal transplant recipients. Transplantation 1993; 56: 103.
Rayes N, Seehofer D, Lullius SG, et al. Monitoring of human cytomegalovirus
, HHV-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation: a prospective study. Ann Transplant 2005; 10: 23.
Schroeder R, Michelon T, Fagundes I, et al. Antigenemia for cytomegalovirus
in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus
disease. Transplant Proc 2005; 37: 2781.
Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus
infection in transplant recipients. J Clin Virol 2008; 41: 237.
Gerna G, Baldanti F, Lilleri D, et al. Human cytomegalovirus
pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation 2003; 75: 1012.
Villa M, Lage E, Ballesteros S, et al. Preemptive therapy for the prevention
disease following heart transplantation directed by pp65 antigenemia. Transplant Proc 2003; 35: 732.
Caliendo AM, St George K, Allega J, et al. Distinguishing cytomegalovirus
) infection and disease with CMV
nucleic acid assays. J Clin Microbiol 2002; 40: 1581.
Lao WC, Lee D, Burroughs A, et al. Use of polymerase chain reaction to provide prognostic information of human cytomegalovirus
disease after liver transplantation. J Med Virol 1997; 51: 152.
Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus
replication during preemptive therapy with oral ganciclovir
. J Infect Dis 2003; 187: 1801.
Rollag H, Sagedal S, Kristiansen KI, et al. Cytomegalovirus
DNA concentration in plasma predicts development of cytomegalovirus
disease in kidney transplant recipients. Clin Microbiol Infect 2002; 8: 431.
Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus
disease after transplantation. Lancet 2000; 355: 2032.
Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus
viral load determination for predicting cytomegalovirus
disease in liver transplant recipients. Transplantation 1999; 68: 1305.
Humar A, Kumar D, Boivin G, et al. Cytomegalovirus
) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV
disease. J Infect Dis 2002; 186: 829.
Piiparinen H, Hockerstedt K, Gronhagen-Riska C, et al. Comparison of two quantitative CMV
PCR tests, Cobas Amplicor CMV
Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004; 30: 258.
Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus
) DNA quantitation in transplant recipients with CMV
disease. Transplantation 2002; 73: 968.
Tang W, Elmore SH, Fan H, et al. Cytomegalovirus
DNA measurement in blood and plasma using Roche LightCycler CMV
quantification reagents. Diagn Mol Pathol 2008; 17: 166.
Hamprecht K, Steinmassl M, Einsele H, et al. Discordant detection of human cytomegalovirus
DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection. J Clin Virol 1998; 11: 125.
Koidl C, Bozic M, Marth E, et al. Detection of CMV
DNA: is EDTA whole blood superior to EDTA plasma? J Virol Methods 2008; 154: 210.
Lisboa LF, Åsberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus
viral load assays for monitoring therapeutic response. Transplantation 2011; 91: 231.
Abdul-Ali D, Kraft CS, Ingersoll J, et al. Cytomegalovirus
DNA stability in EDTA anti-coagulated whole blood and plasma samples. J Clin Virol 2011; 52: 222.
Pang XL, Fox JD, Fenton JM, et al. Interlaboratory comparison of cytomegalovirus
viral load assays. Am J Transplant 2009; 9: 258.
Hirsch HH, Lautenschlager I, Pinsky BA, et al. An international multicenter performance analysis of cytomegalovirus
load tests. Clin Infect Dis 2013; 56: 367.
Hayden RT, Yan X, Wick MT, et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol 2012; 50: 337.
Lilleri D, Lazzarotto T, Ghisetti V, et al. Multicenter quality control study for human cytomegalovirus
DNAemia quantification. New Microbiol 2009; 32: 245.
Manuel O, Åsberg A, Pang X, et al. Impact of genetic polymorphisms in cytomegalovirus
glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus
disease. Clin Infect Dis 2009; 49: 1160.
Martin-Gandul C, Perez-Romero P, Sanchez M, et al. Determination, validation and standardization of a CMV
DNA cut-off value in plasma for preemptive treatment
infection in solid organ transplant recipients at lower risk for CMV
infection. J Clin Virol 2013; 56: 13.
Åsberg A, Humar A, Rollag H, et al. Oral valganciclovir
is noninferior to intravenous ganciclovir
for the treatment
disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
Caliendo AM, Schuurman R, Yen-Lieberman B, et al. Comparison of quantitative and qualitative PCR assays for cytomegalovirus
DNA in plasma. J Clin Microbiol 2001; 39: 1334.
Solans EP, Yong S, Husain AN, et al. Bronchioloalveolar lavage in the diagnosis of CMV
pneumonitis in lung transplant recipients: an immunocytochemical study. Diagn Cytopathol 1997; 16: 350.
Chemaly RF, Yen-Lieberman B, Castilla EA, et al. Correlation between viral loads of cytomegalovirus
in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol 2004; 42: 2168.
Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus
infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
Lautenschlager I, Halme L, Hockerstedt K, et al. Cytomegalovirus
infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006; 8: 21.
Halme L, Lempinen M, Arola J, et al. High frequency of gastroduodenal cytomegalovirus
infection in liver transplant patients. Apmis 2008; 116: 99.
Eid AJ, Arthurs SK, Deziel PJ, et al. Clinical predictors of relapse after treatment
of primary gastrointestinal cytomegalovirus
disease in solid organ transplant recipients. Am J Transplant 2010; 10: 157.
Westall GP, Michaelides A, Williams TJ, et al. Human cytomegalovirus
load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190: 1076.
Storch GA, Ettinger NA, Ockner D, et al. Quantitative cultures of the cell fraction and supernatant of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus
pneumonitis in lung transplant recipients. J Infect Dis 1993; 168: 1502.
Buffone GJ, Frost A, Samo T, et al. The diagnosis of CMV
pneumonitis in lung and heart/lung transplant patients by PCR compared with traditional laboratory criteria. Transplantation 1993; 56: 342.
Riise GC, Andersson R, Bergstrom T, et al. Quantification of cytomegalovirus
DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest 2000; 118: 1653.
Gerna G, Lilleri D, Rognoni V, et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus
infection in lung transplant recipients. Am J Transplant 2009; 9: 1142.
Bauer CC, Jaksch P, Aberle SW, et al. Relationship between cytomegalovirus
DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol 2007; 45: 324.
Puchhammer-Stockl E. Herpesviruses and the transplanted lung: looking at the air side. J Clin Virol 2008; 43: 415.
Crough T, Khanna R. Immunobiology of human cytomegalovirus
: from bench to bedside. Clin Microbiol Rev 2009; 22: 76.
Sester M, Gärtner BC, Sester U. Monitoring of CMV
specific T-cell levels after organ transplantation. J Lab Med 2008; 32: 121.
Gandhi MK, Khanna R. Human cytomegalovirus
: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725.
Kijpittayarit S, Eid AJ, Brown RA, et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus
disease after liver transplantation. Clin Infect Dis 2007; 44: 1315.
Cervera C, Lozano F, Saval N, et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83: 1493.
Manuel O, Pascual M, Trendelenburg M, et al. Association between mannose-binding lectin deficiency and cytomegalovirus
infection after kidney transplantation. Transplantation 2007; 83: 359.
de Rooij BJ, van der Beek MT, van Hoek B, et al. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus
(re)infection after orthotopic liver transplantation. J Hepatol 2011; 55: 800.
Hadaya K, de Rham C, Bandelier C, et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV
infection after kidney transplantation. Am J Transplant 2008; 8: 2674.
Stern M, Elsasser H, Honger G, et al. The number of activating KIR genes inversely correlates with the rate of CMV
infection/reactivation in kidney transplant recipients. Am J Transplant 2008; 8: 1312.
Lilleri D, Kabanova A, Lanzavecchia A, et al. Antibodies against neutralization epitopes of human cytomegalovirus
gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 2012; 32: 1324.
Fouts AE, Chan P, Stephan JP, et al. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus
) neutralizing antibody response in CMV
hyperimmune globulin. J Virol 2012; 86: 7444.
Genini E, Percivalle E, Sarasini A, et al. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus
(HCMV) in primary and reactivated HCMV infections. J Clin Virol 2011; 52: 113.
Corales R, Chua J, Mawhorter S, et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl Infect Dis 2000; 2: 133.
Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71: 242.
Doron S, Ruthazer R, Werner BG, et al. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 2006; 81: 697.
Fernandez-Ruiz M, Lopez-Medrano F, Varela-Pena P, et al. Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection. Am J Transplant 2012; 12: 2763.
Couzi L, Pitard V, Netzer S, et al. Common features of gammadelta T cells and CD8(+) alphabeta T cells responding to human cytomegalovirus
infection in kidney transplant recipients. J Infect Dis 2009; 200: 1415.
Couzi L, Pitard V, Sicard X, et al. Antibody-dependent anti-cytomegalovirus
activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood 2012; 119: 1418.
Presser D, Sester U, Mohrbach J, et al. Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor-based drug regimens. Kidney Int 2009; 76: 557.
Egli A, Silva M Jr, O’Shea D, et al. An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus
replication in solid organ transplant recipients. PLoS One 2012; 7: e43937.
Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus
T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673.
Snyder LD, Medinas R, Chan C, et al. Polyfunctional cytomegalovirus
-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis
. Am J Transplant 2011; 11: 553.
Sester U, Presser D, Dirks J, et al. PD-1 expression and IL-2 loss of cytomegalovirus
-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008; 8: 1486.
Brestrich G, Zwinger S, Roemhild A, et al. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. J Immunother 2009; 32: 932.
Brestrich G, Zwinger S, Fischer A, et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV
disease and resistance
to antiviral therapy. Am J Transplant 2009; 9: 1679.
Walker S, Fazou C, Crough T, et al. Ex vivo monitoring of human cytomegalovirus
T-cell responses using QuantiFERON-CMV
. Transpl Infect Dis 2007; 9: 165.
Westall GP, Mifsud NA, Kotsimbos T. Linking CMV
serostatus to episodes of CMV
reactivation following lung transplantation by measuring CMV
T-cell immunity. Am J Transplant 2008; 8: 1749.
Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus
-specific cell-mediated immunity for the prediction of cytomegalovirus
disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56: 817.
Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus
disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214.
Cantisan S, Lara R, Montejo M, et al. Pretransplant interferon-gamma secretion by CMV
T cells informs the risk of CMV
replication after transplantation. Am J Transplant 2013; 13: 738.
Weseslindtner L, Kerschner H, Steinacher D, et al. Prospective analysis of human cytomegalovirus
DNAemia and specific CD8+
T cell responses in lung transplant recipients. Am J Transplant 2012; 12: 2172.
Lisboa LF, Kumar D, Wilson LE, et al. Clinical utility of cytomegalovirus
cell-mediated immunity in transplant recipients with cytomegalovirus
viremia. Transplantation 2012; 93: 195.
Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus
specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8: 990.
Abate D, Fiscon M, Saldan A, et al. Human cytomegalovirus
-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J Clin Microbiol 2012; 50: 1974.
Abate D, Saldan A, Fiscon M, et al. Evaluation of cytomegalovirus
)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis
, or preemptive therapy but not antithymocyte globulin treatment
contribute to CMV
-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010; 202: 585.
Costa C, Astegiano S, Terlizzi ME, et al. Evaluation and significance of cytomegalovirus
-specific cellular immune response in lung transplant recipients. Transplant Proc 2011; 43: 1159.
Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus
control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287.
Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus
-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6: 2356.
Gerna G, Lilleri D, Chiesa A, et al. Virologic and immunologic monitoring of cytomegalovirus
to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011; 11: 2463.
Sester U, Gartner BC, Wilkens H, et al. Differences in CMV
-specific T-cell levels and long-term susceptibility to CMV
infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5: 1483.
Radha R, Jordan S, Puliyanda D, et al. Cellular immune responses to cytomegalovirus
in renal transplant recipients. Am J Transplant 2005; 5: 110.
Egli A, Binet I, Binggeli S, et al. Cytomegalovirus
-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
Shlobin OA, West EE, Lechtzin N, et al. Persistent cytomegalovirus
-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 2006; 176: 2625.
La Rosa C, Krishnan A, Longmate J, et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus
disease. J Infect Dis 2008; 197: 25.
Sund F, Lidehall AK, Claesson K, et al. CMV
-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplant 2010; 24: 401.
Zeevi A, Husain S, Spichty KJ, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007; 7: 471.
Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus
disease after renal transplant. A controlled trial. Ann Intern Med 1991; 114: 525.
Balfour HH Jr. Options for prevention
disease. Ann Intern Med 1991; 114: 598.
Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus
vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180: 970.
Pass RF, Zhang C, Evans A, et al. Vaccine prevention
of maternal cytomegalovirus
infection. N Engl J Med 2009; 360: 1191.
Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus
glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377: 1256.
Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus
DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12: 290.
Reap EA, Morris J, Dryga SA, et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus
. Vaccine 2007; 25: 7441.
Bernstein DI, Schleiss MR, Berencsi K, et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus
) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV
-seronegative adults. J Infect Dis 2002; 185: 686.
Berencsi K, Gyulai Z, Gonczol E, et al. A canarypox vector-expressing cytomegalovirus
) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV
-seronegative subjects. J Infect Dis 2001; 183: 1171.
Zhong J, Rist M, Cooper L, et al. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus
. PLoS ONE 2008; 3: e3256.
Rubin RH, Kemmerly SA, Conti D, et al. Prevention
of primary cytomegalovirus
disease in organ transplant recipients with oral ganciclovir
or oral acyclovir prophylaxis
. Transpl Infect Dis 2000; 2: 112.
Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir
vs. oral ganciclovir
disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis
in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis
in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus
disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427.
Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus
) disease among CMV
-mismatched solid organ transplant patients receiving prophylaxis
with oral ganciclovir
. J Infect Dis 2001; 184: 1461.
Couzi L, Helou S, Bachelet T, et al. High incidence of anticytomegalovirus drug resistance
among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012; 12: 202.
Atabani SF, Smith C, Atkinson C, et al. Cytomegalovirus
replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012; 12: 2457.
Sun HY, Cacciarelli TV, Wagener MM, et al. Preemptive therapy for cytomegalovirus
based on real-time measurement of viral load in liver transplant recipients. Transpl Immunol 2010; 23: 166.
Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir
for the management of cytomegalovirus
infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis
versus preemptive valganciclovir
therapy to prevent cytomegalovirus
disease after renal transplantation. Am J Transplant 2008; 8: 69.
Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis
with oral ganciclovir
: results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
Witzke O, Hauser IA, Bartels M, et al. Valganciclovir prophylaxis
versus preemptive therapy in cytomegalovirus
-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93: 61.
Åsberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV
versus IV ganciclovir
in solid organ transplant recipients. Am J Transplant 2009; 9: 1205.
Spinner ML, Saab G, Casabar E, et al. Impact of prophylactic versus preemptive valganciclovir
on long-term renal allograft outcomes. Transplantation 2010; 90: 412.
Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of pre-emptive valganciclovir
compared with valacyclovir prophylaxis
in renal transplantation. J Am Soc Nephrol 2012; 23: 1588.
Reischig T, Nemcova J, Vanecek T, et al. Intragraft cytomegalovirus
infection: a randomized trial of valacyclovir prophylaxis
versus pre-emptive therapy in renal transplant recipients. Antivir Ther 2010; 15: 23.
Singh N, Wannstedt C, Keyes L, et al. Indirect outcomes associated with cytomegalovirus
(opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005; 79: 1428.
Bodro M, Sabe N, Llado L, et al. Prophylaxis
versus preemptive therapy for cytomegalovirus
disease in high-risk liver transplant recipients. Liver Transpl 2012; 18: 1093.
Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus
replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11: 2190.
Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus
pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 1391.
Zuk DM, Humar A, Weinkauf JG, et al. An international survey of cytomegalovirus
management practices in lung transplantation. Transplantation 2010; 90: 672.
BenMarzouk-Hidalgo OJ, Cordero E, Gomez-Cia T, et al. First face composite-tissue transplant recipient successfully treated for cytomegalovirus
infection with preemptive valganciclovir treatment
. Antimicrobial Agents Chemother 2011; 55: 5949.
Bonatti H, Brandacher G, Margreiter R, et al. Infectious complications in three double hand recipients: experience from a single center. Transplant Proc 2009; 41: 517.
Schneeberger S, Lucchina S, Lanzetta M, et al. Cytomegalovirus
-related complications in human hand transplantation. Transplantation 2005; 80: 441.
Gordon CR, Abouhassan W, Avery RK. What is the true significance of donor-related cytomegalovirus
transmission in the setting of facial composite tissue allotransplantation? Transplant Proc 2011; 43: 3516.
Gordon CR, Avery RK, Abouhassan W, et al. Cytomegalovirus
and other infectious issues related to face transplantation: specific considerations, lessons learned, and future recommendations. Plast Reconstr Surg 2011; 127: 1515.
Lisboa LF, Preiksaitis JK, Humar A, et al. Clinical utility of molecular surveillance for cytomegalovirus
after antiviral prophylaxis
in high-risk solid organ transplant recipients. Transplantation 2011; 92: 1063.
Montejo M, Montejo E, Gastaca M, et al. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus
D+/R-) liver transplant recipients: a single-center experience. Transplant Proc 2009; 41: 2189.
Boillat Blanco N, Pascual M, Venetz JP, et al. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis
in kidney transplant recipients. Transplantation 2011; 91: 251.
van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment
regimens for cytomegalovirus
in renal transplantation: comparison of treatment
failure and antiviral resistance
. Transplantation 2010; 89: 320.
Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus
in organ transplant recipients in the era of antiviral prophylaxis
. Transplantation 2006; 81: 1645.
Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus
disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
Moreno A, Cervera C, Fortun J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl 2012; 18: 70.
San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus
disease after renal transplantation. Clin Infect Dis 2008; 47: 875.
Ozaki KS, Camara NO, Nogueira E, et al. The use of sirolimus in ganciclovir
infections in renal transplant recipients. Clin Transplant 2007; 21: 675.
Fortun J, Martin-Davila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12: 397.
Cervera C, Fernandez-Ruiz M, Valledor A, et al. Epidemiology and risk factors for late infection in solid organ transplant recipients. Transpl Infect Dis 2011; 13: 598.
Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004.
Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus
incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453.
Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus
infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075.
Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis
with intravenous ganciclovir
immune globulin, valganciclovir
is safe and effective for prevention
infection following lung transplantation. Am J Transplant 2004; 4: 1635.
Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention
in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir
therapy. J Heart Lung Transplant 2009; 28: 670.
Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis
to prevent cytomegalovirus
after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761.
Schoeppler KE, Lyu DM, Grazia TJ, et al. Late-onset cytomegalovirus
) in lung transplant recipients: can CMV
serostatus guide the duration of prophylaxis
? Am J Transplant 2013; 13: 376.
Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention
disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis
Transplantation Study Group. N Engl J Med 1999; 340: 1462.
Pavlopoulou ID, Syriopoulou VP, Chelioti H, et al. A comparative randomised study of valacyclovir vs. oral ganciclovir
for cytomegalovirus prophylaxis
in renal transplant recipients. Clin Microbiol Infect 2005; 11: 736.
Reischig T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis
reduces the risk of acute renal allograft rejection. Transplantation 2005; 79: 317.
Kielberger L, Bouda M, Jindra P, et al. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus
infection in renal transplant recipients. Kidney Blood Press Res 2012; 35: 407.
Park JM, Lake KD, Arenas JD, et al. Efficacy and safety of low-dose valganciclovir
in the prevention
disease in adult liver transplant recipients. Liver Transpl 2006; 12: 112.
Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus
disease after liver transplantation. Liver Transpl 2007; 13: 1703.
Brady RL, Green K, Frei C, et al. Oral ganciclovir
for cytomegalovirus prophylaxis
in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11: 106.
Fayek SA, Mantipisitkul W, Rasetto F, et al. Valganciclovir
is an effective prophylaxis
disease in liver transplant recipients. HPB (Oxford) 2010; 12: 657.
Shiley KT, Gasink LB, Barton TD, et al. Increased incidence of cytomegalovirus
infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis
versus ganciclovir prophylaxis
. Liver Transpl 2009; 15: 963.
Levitsky J, Singh N, Wagener MM, et al. A survey of CMV prevention
strategies after liver transplantation. Am J Transplant 2008; 8: 158.
Greiner M, Cusini A, Ruesch M, et al. A stringent preemptive protocol reduces cytomegalovirus
disease in the first 6 months after kidney transplantation. Infection 2012; 40: 669.
Atabani SF, Emery VC, Smith C, et al. Response to letter regarding “cytomegalovirus
replication kinetics in solid organ transplant recipients managed by preemptive therapy”. Am J Transplant 2012; 12: 2859.
Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir
therapy to prevent cytomegalovirus
disease in cytomegalovirus
antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18.
Lefeuvre S, Chevalier P, Charpentier C, et al. Valganciclovir prophylaxis
infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure. Transpl Infect Dis 2010; 12: 213.
Radeva G, Buyse M, Hindlet P, et al. Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis. Dig Dis Sci 2007; 52: 1653.
Emery VC, Griffiths PD. Prediction of cytomegalovirus
load and resistance
patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000; 97: 8039.
McGavin JK, Goa KL. Ganciclovir
: an update of its use in the prevention
infection and disease in transplant recipients. Drugs 2001; 61: 1153.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247.
Chou SW. Cytomegalovirus
and clinical implications. Transpl Infect Dis 2001; 3: 20.
Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus
) DNA load predicts relapsing CMV
infection after solid organ transplantation. J Infect Dis 2000; 181: 717.
Falagas ME, Snydman DR, Griffith J, et al. Clinical and epidemiological predictors of recurrent cytomegalovirus
disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1997; 25: 314.
Humar A, Uknis M, Carlone-Jambor C, et al. Cytomegalovirus
disease recurrence after ganciclovir treatment
in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 94.
Åsberg A, Jardine AG, Bignamini AA, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment
disease in organ transplant recipients. Am J Transplant 2010; 10: 1881.
Shanahan A, Malani PN, Kaul DR. Relapsing cytomegalovirus
infection in solid organ transplant recipients. Transpl Infect Dis 2009; 11: 513.
Sommadossi JP, Bevan R, Ling T, et al. Clinical pharmacokinetics of ganciclovir
in patients with normal and impaired renal function. Rev Infect Dis 1988; 10: S507.
Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. Herpes 2003; 10: 12.
Sarmiento E, Fernandez-Yanez J, Munoz P, et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV
disease. Int Immunopharmacol 2005; 5: 97.
Sarmiento E, Rodriguez-Molina J, Munoz P, et al. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation. Transpl Proc 2005; 37: 4046.
Sarmiento E, Rodriguez-Molina JJ, Fernandez-Yanez J, et al. IgG monitoring to identify the risk for development of infection in heart transplant recipients. Transpl Infect Dis 2006; 8: 49.
Lurain NS, Chou S. Antiviral drug resistance
of human cytomegalovirus
. Clin Microbiol Rev 2010; 23: 689.
Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance
in solid organ transplant recipients treated with intravenous ganciclovir
or oral valganciclovir
. Antivir Ther 2009; 14: 697.
Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus
in transplant recipients: a French cohort study. J Antimicrob Chemother 2010; 65: 2628.
Myhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir
infections in 1244 kidney transplant recipients. Transplantation 2011; 92: 217.
Boivin G, Goyette N, Farhan M, et al. Incidence of cytomegalovirus
UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis
. J Clin Virol 2012; 53: 208.
Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus
in the era of valganciclovir prophylaxis
: therapeutic implications and outcomes. Clin Transplant 2008; 22: 162.
Chevillotte M, von Einem J, Meier BM, et al. A new tool linking human cytomegalovirus
mutations to resistance
phenotypes. Antiviral Res 2010; 85: 318.
Perrottet N, Decosterd LA, Meylan P, et al. Valganciclovir
in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 2009; 48: 399.
Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus
infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388.
Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment
of complex cytomegalovirus
syndromes. Transplantation 2010; 90: 419.
Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus
infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46: 1455.
Wolf DG, Shimoni A, Resnick IB, et al. Human cytomegalovirus
kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011; 90: 183.
Painter W, Robertson A, Trost LC, et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56: 2726.
Papanicolaou G, Mommeja-Marin H, Anderson M, et al. CMX001 Is an Effective Treatment
Option for Refractory Cytomegalovirus
Infection or Disease in Hematopoietic Cell Transplant Recipients: A Single Center Experience. San Francisco, CA: 52nd Intersci Conf Antimicrob Agents Chemother; 2012: Abstract T.
Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus
replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002; 46: 2365.
Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis
disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11: 284.
Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention
disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 2012; 12: 3021.
Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment
of refractory or resistant cytomegalovirus
infections in transplant recipients. Transpl Infect Dis 2010; 12: 489.
Strasfeld L, Lee I, Villano S, et al. Virologic characterization of multi-drug-resistant cytomegalovirus
infection in two transplant recipients treated with maribavir. J Infect Dis 2010; 202: 104.
Chou S, Hakki M, Villano S. Effects on maribavir susceptibility of cytomegalovirus
UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. Antiviral Res 2012; 95: 88.
Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54: 1290.
Chemaly RF, Ehninger G, Champlin R, et al. Letermovir (AIC246) for the Prevention
Infections Meets Primary Endpoint in Phase 2b Trial in Human Blood Precursor Cell Transplant Recipients. San Francisco, CA: 52nd Intersci Conf Antimicrob Agents Chemother; 2012: Abstract T.
Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment
of multidrug-resistant cytomegalovirus
disease with the novel anti-CMV
compound AIC246. Am J Transplant 2011; 11: 1079.
Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus
replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85: 10884.
. Infectious Diseases Community of Practice, American Society of Transplantation. Guidelines for the prevention
and management of infectious complications of solid organ transplantation. Am J Transplant 2004; 4: 51.
Humar A, Snydman D. Cytomegalovirus
in solid organ transplant recipients. Am J Transplant 2009; 9: S78.
Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus
management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
Bowman JS, Green M, Scantlebury VP, et al. OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant 1991; 5: 294.
Iragorri S, Pillay D, Scrine M, et al. Prospective cytomegalovirus
surveillance in paediatric renal transplant patients. Pediatr Nephrol 1993; 7: 55.
Green M, Michaels MG, Katz BZ, et al. CMV
-IVIG for prevention
of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906.
Bueno J, Green M, Kocoshis S, et al. Cytomegalovirus
infection after intestinal transplantation in children. Clin Infect Dis 1997; 25: 1078.
Nayyar N, Mazariegos G, Ranganathan S, et al. Pediatric small bowel transplantation. Semin Pediatr Surg 2010; 19: 68.
Kranz B, Vester U, Wingen AM, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus
infection. Pediatr Transplant 2008; 12: 474.
Smith JM, Corey L, Bittner R, et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21: 1579.
Danziger-Isakov LA, DelaMorena M, Hayashi RJ, et al. Cytomegalovirus
viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 2003; 75: 1538.
Danziger-Isakov LA, Worley S, Michaels MG, et al. The risk, prevention
, and outcome of cytomegalovirus
after pediatric lung transplantation. Transplantation 2009; 87: 1541.
Bueno J, Ramil C, Green M. Current management strategies for the prevention
infection in pediatric transplant recipients. Paediatr Drugs 2002; 4: 279.
Paya CV. Indirect effects of CMV
in the solid organ transplant patient. Transpl Infect Dis 1999; 1: 8.
Danziger-Isakov LA, Worley S, Arrigain S, et al. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant 2008; 27: 655.
Liu M, Worley S, Arrigain S, et al. Respiratory viral infections within one year after pediatric lung transplant. Transpl Infect Dis 2009; 11: 304.
Snydman DR, Kistler KD, Ulsh P, et al. Cytomegalovirus prevention
and long-term recipient and graft survival in pediatric heart transplant recipients. Transplantation 2010; 90: 1432.
Hussain T, Burch M, Fenton MJ, et al. Positive pretransplantation cytomegalovirus
serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007; 115: 1798.
Mahle WT, Fourshee MT, Naftel DM, et al. Does cytomegalovirus
serology impact outcome after pediatric heart transplantation? J Heart Lung Transplant 2009; 28: 1299.
Patel M, Stefanidou M, Long CB, et al. Dynamics of cell-mediated immune responses to cytomegalovirus
in pediatric transplantation recipients. Pediatr Transplant 2012; 16: 18.
Madan RP, Campbell AL, Shust GF, et al. A hybrid strategy for the prevention
-related complications in pediatric liver transplantation recipients. Transplantation 2009; 87: 1318.
Lin A, Worley S, Brubaker J, et al. Assessment of cytomegalovirus
hybrid preventative strategy in pediatric heart transplant patients. J Pediatr Infect Dis Soc 2012. doi: 10.1093/jpids/pis056.
Green M, Kaufmann M, Wilson J, et al. Comparison of intravenous ganciclovir
followed by oral acyclovir with intravenous ganciclovir
alone for prevention
and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997; 25: 1344.
Spivey JF, Singleton D, Sweet S, et al. Safety and efficacy of prolonged cytomegalovirus prophylaxis
with intravenous ganciclovir
in pediatric and young adult lung transplant recipients. Pediatr Transplant 2007; 11: 312.
Pescovitz MD, Jain A, Robson R, et al. Establishing pharmacokinetic bioequivalence of valganciclovir
oral solution versus the tablet formulation. Transplant Proc 2007; 39: 3111.
Vaudry W, Ettenger R, Jara P, et al. Valganciclovir
dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009; 9: 636.
Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir
in the treatment
of symptomatic congenital cytomegalovirus
disease. J Infect Dis 2008; 197: 836.
Bedel AN, Hemmelgarn TS, Kohli R. Retrospective review of the incidence of cytomegalovirus
infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir
. Liver Transpl 2012; 18: 347.
Saitoh A, Sakamoto S, Fukuda A, et al. A universal preemptive therapy for cytomegalovirus
infections in children after live-donor liver transplantation. Transplantation 2011; 92: 930.
Krampe K, Briem-Richter A, Fischer L, et al. The value of immunoprophylaxis for cytomegalovirus
infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen. Pediatr Transplant 2010; 14: 67.
Florescu DF, Langnas AN, Grant W, et al. Incidence, risk factors, and outcomes associated with cytomegalovirus
disease in small bowel transplant recipients. Pediatr Transplant 2012; 16: 294.
Ranganathan K, Worley S, Michaels MG, et al. Cytomegalovirus
immunoglobulin decreases the risk of cytomegalovirus
infection but not disease after pediatric lung transplantation. J Heart Lung Transplant 2009; 28: 1050.
Snydman DR, Kistler KD, Ulsh P, et al. The impact of CMV prevention
on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database. Clin Transplant 2011; 25: E455.
Gilbert C, Boivin G. Human cytomegalovirus resistance
to antiviral drugs. Antimicrob Agents Chemother 2005; 49: 873.
Freeman RB Jr. The ‘indirect’ effects of cytomegalovirus
infection. Am J Transplant 2009; 9: 2453.
Reischig T, Jindra P, Hes O, et al. Effect of cytomegalovirus
viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis
. Transplantation 2009; 87: 436.
Bosch W, Heckman MG, Pungpapong S, et al. Association of cytomegalovirus
infection and disease with recurrent hepatitis C after liver transplantation. Transplantation 2012; 93: 723.
Gunsar F, Rolando N, Pastacaldi S, et al. Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transpl 2003; 9: 605.
Silva MA, Jambulingam PS, Gunson BK, et al. Hepatic artery thrombosis following orthotopic liver transplantation: a 10-year experience from a single centre in the United Kingdom. Liver Transpl 2006; 12: 146.
Seehofer D, Rayes N, Tullius SG, et al. CMV
hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up. Liver Transpl 2002; 8: 1138.
Potena L, Grigioni F, Magnani G, et al. Prophylaxis
versus preemptive anti-cytomegalovirus
approach for prevention
of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009; 28: 461.
Petrakopoulou P, Kubrich M, Pehlivanli S, et al. Cytomegalovirus
infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004; 110: II207.
Johanssson I, Martensson G, Andersson R. Cytomegalovirus
and long-term outcome after lung transplantation in Gothenburg, Sweden. Scand J Infect Dis 2010; 42: 129.
Chmiel C, Speich R, Hofer M, et al. Ganciclovir
-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46: 831.
Linares L, Sanclemente G, Cervera C, et al. Influence of cytomegalovirus
disease in outcome of solid organ transplant patients. Transplant Proc 2011; 43: 2145.
Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis
on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39: 1293.
Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346.
Gomez E, Laures A, Baltar JM, et al. Cytomegalovirus
replication and “herpesvirus burden” as risk factor of cardiovascular events in the first year after renal transplantation. Transplant Proc 2005; 37: 3760.
Van Laecke S, Desideri F, Geerts A, et al. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transpl 2010; 16: 1278.
Leung Ki EL, Venetz JP, Meylan P, et al. Cytomegalovirus
infection and new-onset post-transplant diabetes mellitus. Clin Transplant 2008; 22: 245.
Koch S, Larbi A, Ozcelik D, et al. Cytomegalovirus
infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 2007; 1114: 23.
Monforte V, Lopez C, Santos F, et al. A multicenter study of valganciclovir prophylaxis
up to day 120 in CMV
-seropositive lung transplant recipients. Am J Transplant 2009; 9: 1134.
Sagedal S, Rollag H, Hartmann A. Cytomegalovirus
infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007; 21: 309.
Kotton CN. CMV
, diagnosis and therapy. Am J Transplant 2013; 13: 24.
Dzabic M, Rahbar A, Yaiw KC, et al. Intragraft cytomegalovirus
protein expression is associated with reduced renal allograft survival. Clin Infect Dis 2011; 53: 969.
Guyatt GH, Oxman AD, Kunz R, et al. What is “quality of evidence” and why is it important to clinicians? BMJ 2008; 336: 995.
APPENDIX 1 Consensus Contributors (in alphabetical order)
Leaders: Camille N. Kotton (USA) and Atul Humar (Canada)
Diagnostics: Angela M. Caliendo (leader, USA), Irmeli Lautenschlager (Finland), Jutta Preiksaitis (Canada)
Immunology: Deepali Kumar (leader, Canada), Davide Abate (Italy), Vincent Emery (United Kingdom), Rajiv Khanna (Australia), Daniele Lilleri (Italy), Oriol Manuel (Switzerland), Martina Sester (Germany)
Prevention: Atul Humar (coleader, Canada) and Camille N. Kotton (coleader, USA), Emily Blumberg (USA), Luis F.A. Camargo (Brazil), Chad Gordon (USA), Shirish Huprikar (USA), Nassim Kamar (France), Roberta Lattes (Argentina), Pierre Merville (France), Nicolas Mueller (Switzerland), Graham Paget (South Africa), Tomas Reischig (Czech Republic), Nina Singh (USA), David R. Snydman (USA), Julian Torre-Cisneros (Spain), Glen Westall (Australia), Martin Zamora (USA)
Treatment: Anders Åsberg (leader, Norway), Jennifer Harrison (Canada), Michele Morris (USA), Patricia Munoz (Spain), William Rawlinson (Australia)
Resistance: Sunwen Chou (leader, USA), Sophie Alain (France), Fausto Baldanti (Italy), Ajit P. Limaye (USA), Nell Lurain (USA)
Pediatrics: Lara Danziger-Isakov (leader, USA), Upton Allen (Canada), Michael Green (USA), Betsy C. Herold (USA), Marian Michaels (USA)